A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The purpose of the study is to assess the safety, efficacy and pharmacokinetics of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or IX in 12 patients ( birth to \<6 years old), and 12 patients (≥6 years old to \<12 years old).
Epistemonikos ID: 4db2bd29dbba0479bb5a9d4bbc53f8973fd0f548
First added on: May 12, 2024